- The intravenous nucleic acid therapeutics market is at the forefront of medical innovation, offering targeted approaches to treat a range of diseases. This market is driven by significant advancements in molecular biology and drug delivery, addressing critical unmet needs in global health
- The escalating demand for Intravenous nucleic acid therapeutics is primarily fueled by the increasing prevalence of genetic and chronic diseases, breakthroughs in gene editing and RNA interference technologies, and a rising preference for highly specific and personalized treatment options. Ongoing research and development efforts, coupled with growing investments from pharmaceutical and biotechnology companies, are consistently expanding the pipeline of novel nucleic acid therapies
- North America dominated the intravenous nucleic acid therapeutics market with the largest revenue share of 35.9% in 2024. This dominance is characterized by significant R&D investments, a robust biopharmaceutical ecosystem, and a favorable regulatory environment, particularly in the U.S.
- Asia-Pacific is expected to be the fastest-growing region in the intravenous nucleic acid therapeutics market during the forecast period, with a projected CAGR of 17.9%. This growth is driven by increasing healthcare expenditure, a rising prevalence of chronic and genetic disorders, improving healthcare infrastructure, and growing awareness of advanced therapies in countries such as China, India, and Japan
- The small interfering RNAs (siRNAs) segment dominated the intravenous nucleic acid therapeutics market with a market share of 45.6%. This dominance is driven by the successful clinical translation and regulatory approvals of several RNAi-based drugs for rare genetic disorders and other conditions, demonstrating their established efficacy and safety profiles
